Zolenzepine

Zileuton (Zyflo&trade) is a reversible 5-LO inhibitor that was approved in 1997 for the prevention and treatment of asthma in the USA, but was withdrawn by Abbott Laboratories in 2003. Zileuton inhibits 5-LO from rat basophilic leukemia-1 (RBL-1)

Zilpaterol belongs to the group of &#946 -adrenergic agonists, used in the treatment of lung diseases due to its brochodilating nature. It is also widely used in veterinary medicine as a growth promoter for increasing muscle gain and decreasing

Zirconium(IV) oxynitrate hydrate.

Zirconium(IV) oxynitrate hydrate.

Zirconium(IV) oxynitrate hydrate.

A dual inhibitor of COX and 5-LO enzymes (IC₅₀ = 0.73, 0.31, and 0.99 &muM for COX-1, COX-2, and 5-LO, respectively, in whole blood).

Biochem/physiol Actions ZLN024 is an allosteric activator of AMPK hetero-trimers. The compound ZLN024 protects against dephosphorylation of Thr172, which is critical for activity, and antagonizes AMPK autoinhibition.

ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1 , AMPK α2β1γ1 , AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC 50 s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.In VitroZLN024

ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1 , AMPK α2β1γ1 , AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC 50 s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.In VitroZLN024

ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1 , AMPK α2β1γ1 , AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC 50 s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.In VitroZLN024

ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1 , AMPK α2β1γ1 , AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC 50 s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.In VitroZLN024

InformationZM 323881 is a potent and selectiveVEGFR2inhibitor withIC50of &lt:2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.In vitroZM323881 inhibits VEGF-A, EGF and bFEF induced HUVEC cell proliferation with IC50 of 8 nM, 1.9 μM